Sign in Subscribe
Class action lawsuits

Rocket Pharmaceuticals Securities Class Action Lawsuit Filed

Strategic Insights

— 2 min read

Rocket Pharmaceuticals' securities class action lawsuit was filed for investors who purchased Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025. The class action lawsuit alleges that Rocket Pharmaceuticals provided false and misleading statements to investors concerning the safety and clinical trial protocol of RP-A501. The company amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders. As a result, investors purchased Rocket Pharmaceuticals securities at artificially inflated prices, leading to damages when the true details entered the market.

Key Takeaways:

  • The lawsuit was filed by the Rosen Law Firm, a global investor rights law firm, on behalf of investors who purchased Rocket Pharmaceuticals securities during the Class Period (February 27, 2025 to May 26, 2025).
  • The lawsuit alleges that Rocket Pharmaceuticals provided false and misleading statements to investors concerning the safety and clinical trial protocol of RP-A501.
  • The company amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders.
  • Investors who purchased Rocket Pharmaceuticals securities during the Class Period may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.
  • A lead plaintiff is needed to represent the class, and individuals must move the Court no later than August 11, 2025, to serve in this role.
  • The Rosen Law Firm has a track record of success in leadership roles, having achieved the largest-ever securities class action settlement against a Chinese company in 2017 and recovering hundreds of millions of dollars for investors in previous cases.

Statistics:

  • The lawsuit covers investors who purchased Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025.
  • The Class Period began on February 27, 2025, when Rocket Pharmaceuticals released its statements to investors.
  • A lead plaintiff must move the Court no later than August 11, 2025, to serve in this role.
  • The Rosen Law Firm has recovered over $438 million for investors in 2019 and has secured numerous securities class action settlements.
  • The firm has been ranked in the top 4 each year since 2013 by ISS Securities Class Action Services for number of securities class action settlements.

Sources:

  • Newsfile Corp. - July 15, 2025
  • Rosenlegal - submit-form/?case_id=40316
  • LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm
  • Twitter: https://twitter.com/rosen_firm
  • Facebook: https://www.facebook.com/rosenlawfirm
  • The Rosen Law Firm, P.A. - 275 Madison Avenue, 40th Floor, New York, NY 10016
  • Phone: (212) 686-1060
  • Toll-Free: (866) 767-3653
  • Fax: (212) 202-3827
  • Email: case@rosenlegal.com
  • Website: www.rosenlegal.com

Read more